

Safety evaluation of an intra-nasally applied cocktail of *Lactococcus lactis* strains in pigs

Ruth Rattigan¹, Lukasz Wajda¹, Abel A. Vlasblom², Alan Wolfe³, Aldert L. Zomer², Birgitta Duim², Jaap A. Wagenaar², Peadar Lawlor^{1*}

¹Pig Development Department, Animal and Grassland Research and Innovation Centre, Teagasc, Moorepark, Fermoy, Co. Cork, Ireland

²Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL, Utrecht, Netherlands

³School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.

*Corresponding author: peadar.lawlor@teagasc.ie

Supplementary Table S1. Composition of the experimental diets (on an air-dry basis; kg/tonne).

| Diet Number | 1 | 2 | 3 | 4 | 5 |
|--|---------|-----------|---------|-------|--------|
| Diet type | Dry sow | Lactation | Starter | Link | Weaner |
| Ingredients | | | | | |
| Barley | 759.7 | 259.7 | 50.0 | 68.4 | 495.9 |
| Wheat | 0 | 455.2 | 0 | 100.0 | 216.8 |
| Maize | 0 | 0 | 231.0 | 300.0 | 0 |
| Soybean meal | 76.2 | 179.8 | 143.4 | 186.9 | 163.2 |
| Full fat soybean meal | 0 | 0 | 130.8 | 70.0 | 50.0 |
| Lactoflo ¹ | 0 | 0 | 200.0 | 150.0 | 0 |
| Skim milk powder | 0 | 0 | 125.0 | 50.0 | 0 |
| Soya hulls | 125.3 | 0 | 0 | 0 | 0 |
| Soya oil | 14.0 | 66.0 | 85.0 | 38.2 | 40.0 |
| Premix ² | 1.5 | 1.5 | 3.0 | 3.0 | 3.0 |
| L-Lysine HCl | 2.3 | 5.0 | 6.2 | 6.7 | 5.9 |
| DL-Methionine | 0.4 | 1.5 | 3.6 | 3.2 | 2.2 |
| L-Threonine | 1.0 | 2.7 | 3.7 | 3.4 | 2.7 |
| L-Tryptophan | 0 | 0.8 | 1.4 | 1.3 | 0.6 |
| L-Valine | 0 | 2.7 | 1.3 | 1.3 | 0.6 |
| Limestone flour | 8.5 | 11.5 | 7.0 | 7.5 | 10.5 |
| Mono dicalcium phosphate | 7.0 | 8.5 | 5.5 | 7.0 | 5.5 |
| Salt | 4.0 | 5.0 | 3.0 | 3.0 | 3.0 |
| Phytase ³ | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Chemical composition | | | | | |
| Dry matter ⁴ | 883.0 | 893.0 | 907.0 | 897.0 | 888.0 |
| Crude protein ⁴ | 125.0 | 163.0 | 188.0 | 166.0 | 178.0 |
| Ash ⁴ | 42.0 | 48.0 | 57.0 | 53.0 | 47.0 |
| Ether extract ⁴ | 33.7 | 85.4 | 119.1 | 58.4 | 65.2 |
| Crude fibre ⁴ | 87.0 | 26.0 | 16.0 | 33.0 | 32.0 |
| Lysine ⁵ | 7.8 | 11.5 | 16.2 | 15.0 | 13.0 |
| Methionine ⁵ | 2.4 | 3.9 | 7.0 | 6.1 | 4.7 |
| Cystine ⁵ | 2.5 | 3.0 | 2.7 | 2.9 | 3.1 |
| Threonine ⁵ | 5.6 | 8.3 | 10.9 | 10.1 | 8.8 |
| Tryptophan ⁵ | 3.66 | 3.36 | 2.66 | 2.22 | 1.54 |
| Digestible energy (MJ/Kg) ⁵ | 12.51 | 14.86 | 16.20 | 15.00 | 14.27 |
| Net energy (MJ/Kg) ⁵ | 8.86 | 10.90 | 12.06 | 10.94 | 10.30 |
| SID lysine ^{5,6} | 6.6 | 10.7 | 15.3 | 14.1 | 12.0 |
| Total calcium ⁵ | 7.2 | 8.3 | 8.2 | 7.5 | 7.4 |
| Digestible phosphorus ⁵ | 3.5 | 3.8 | 4.6 | 4.2 | 3.3 |

¹Lactoflo, non-hygroscopic whey permeate powder (Volac, Royston, United Kingdom)

²Premix provided per kilogram of complete diet Diets 1 and 2): Premix provided per kg of complete diet: Cu from copper sulphate, 15 mg; Fe from ferrous sulphate monohydrate, 70 mg; Mn from manganese oxide, 62 mg; Zn from zinc oxide, 80 mg, I from calcium iodate, 0.6 mg; Se from sodium selenite, 0.2 mg; vitamin A as retinyl acetate, 3.44 mg; vitamin D₃ as cholecalciferol, 25 mg; vitamin E as DL-alpha-tocopheryl acetate, 100 mg; vitamin K, 2 mg; vitamin B₁₂, 15 µg; riboflavin, 5 mg; nicotinic acid, 12 mg; pantothenic acid, 10 mg; choline chloride, 500 mg; Biotin, 200µg; folic acid, 5mg; vitamin B₁,2 mg; and vitamin B₆, 3 mg.Premix provided per kilogram of complete diet (Diet 3, 4 and

5): Premix provided per kilogram of complete diet: Cu from copper sulphate, 85 mg; Fe from ferrous sulphate monohydrate, 90 mg; Mn from manganese oxide, 47 mg; Zn from zinc oxide, 120 mg; I from potassium iodate, 0.6 mg; Se from sodium selenite, 0.3 mg; vitamin A as retinyl acetate, 2.1 mg; vitamin D₃ as cholecalciferol, 25 µg; vitamin E as DL-alpha-tocopheryl acetate, 100 mg; vitamin K, 4 mg; vitamin B₁₂, 15 µg; riboflavin, 2 mg; nicotinic acid, 12 mg; pantothenic acid, 10 mg; choline chloride, 250 mg; vitamin B₁, 2 mg; and vitamin B₆, 3 mg.

³The diet contained 500 phytase units (FYT) per kg feed (RONOZYME HiPhos GT; DSM, Belfast, UK).

⁴Analysed nutrient composition

⁵Calculated nutrient composition

⁶SID lysine = Standardized ileal digestible lysine.

Supplementary Table S2. Health check scoring system.

| Category | Score | | | |
|-----------------------|---|---|--|--|
| | 0 | 1 | 2 | 3 |
| Faecal score | NORMAL <ul style="list-style-type: none"> • Dry, pelleted faeces | SOFT <ul style="list-style-type: none"> • Soft with shape | MILD DIARRHOEA <ul style="list-style-type: none"> • Very soft or viscous liquid | SEVERE DIARRHOEA <ul style="list-style-type: none"> • Watery or with blood |
| Behaviour | NORMAL <ul style="list-style-type: none"> • Active | APATHETIC <ul style="list-style-type: none"> • Must be stimulated to get up | LYING <ul style="list-style-type: none"> • Gets up with help | DEEP PROSTRATION <ul style="list-style-type: none"> • Cannot get up |
| Dehydration | NORMAL <ul style="list-style-type: none"> • No signs/symptoms of dehydration | MILD <ul style="list-style-type: none"> • Normal eyes • Slight reduction of skin elasticity • Normal capillary refill time • Normal mucous membranes | MODERATE <ul style="list-style-type: none"> • Slightly sunken eyes • Loss of skin elasticity • Normal capillary refill time • Normal mucous membranes | SEVERE <ul style="list-style-type: none"> • Sunken eyes • Loose, wrinkled skin very evident • Retarded capillary refill time • Dry mucous membranes |
| Clinical signs | NORMAL <ul style="list-style-type: none"> • Normal Temperature, Respiration/Cardiac rates | MINOR <ul style="list-style-type: none"> • Minor changes in Temperature, Respiration/Cardiac rates | MODERATE <ul style="list-style-type: none"> • Temperature ± 1°C, Respiration/Cardiac rates ±30% | SEVERE <ul style="list-style-type: none"> • Temperature± 2°C, Respiration/Cardiac rates ±50% |

Supplementary Table S3. qPCR primers

| Gene | GenBank accession number | Primers sequences (5' – 3') |
|----------------|--------------------------|---|
| <i>β-actin</i> | U07786.1 | F: CATCACCATCGGCAACGA R: GCGTAGAGGTCCCTTCCTGATGT |
| <i>CXCL8</i> | NM213867 | F: TAGGACCAGAGCCAGGAAGA R: GAACTGCAGCCTCACAGAGA |
| <i>IL6</i> | M86722.1 | F: TGGATAAGCTGCAGTCACAG R: ATTATCCGAATGGCCCTCAG |
| <i>IL1β</i> | M86725.1 | F: AAGTGATGGCTAACTACGGTGAC R: ATCTGCCTGATGCTCTTGTCC |
| <i>TNFα</i> | X57321.1 | F: CACCACGCTCTTCTGCCTACTGC R: TCGGCTTTGACATTGGCTACAA |
| <i>pBD2</i> | AY506573.1 | F: ACCTGCTTACGGGTCTTG R: CTCTGCTGTGGCTTCTGG |
| <i>TLR2</i> | AB072190 | F: ACATGAAGATGATGTGGGCC R: TAGGAGTCCTGCTCACTGTA |
| <i>TLR9</i> | AB071394 | F: GTGGAAGTGTGTTTGGCATC R: CACAGCACTCTGAGCTTTGT |

β-actin, beta-actin; *CXCL8*, C-X-C motif chemokine ligand 8 (*IL8*); *IL6*, interleukin 6; *IL1 β*, interleukin 1-beta; *TNFα*, tumour necrosis factor alpha; *pBD2*, beta-defensin 2; *TLR2*, toll like receptor 2; *TLR9*, toll like receptor 9.

Supplementary Table S4. The effect of treatment on histopathology of the nasal conchae.

| Treatment Group | Placebo | Bacterial Cocktail |
|---------------------------------|---------|--------------------|
| No abnormalities | | |
| 24h after birth | 3/6 | 6/6 |
| 96h after birth | 6/6 | 6/6 |
| 14d after birth | 6/6 | 6/6 |
| Non-significant findings | | |
| 24h after birth | 3/6 | 0/6 |
| 96h after birth | 0/6 | 0/6 |
| 14d after birth | 0/6 | 0/6 |

* Minor changes in epithelium and/or cellular debris in the lumen

Supplementary Table S5. The effect of treatment on the histopathology of the left and right tonsil paraepiglottal.

| Treatment Group | Left | | Right | |
|-------------------------------------|---------|--------------------|---------|--------------------|
| | Placebo | Bacterial Cocktail | Placebo | Bacterial Cocktail |
| No lymphoid tissue collected | | | | |
| 24h after birth | 6/6 | 5/6 | 5/6 | 6/6 |
| 96h after birth | 5/6 | 6/6 | 6/6 | 6/6 |
| 14d after birth | 4/6 | 4/6 | 4/6 | 3/6 |
| No abnormalities | | | | |
| 24h after birth | 0/6 | 1/6 | 1/6 | 0/6 |
| 96h after birth | 0/6 | 0/6 | 0/6 | 0/6 |
| 14d after birth | 2/6 | 2/6 | 2/6 | 3/6 |
| Non-significant findings | | | | |
| 24h after birth | 0/6 | 0/6 | 0/6 | 0/6 |
| 96h after birth | 1/6 | 0/6 | 0/6 | 0/6 |
| 14d after birth | 0/6 | 0/6 | 0/6 | 0/6 |

* Normal findings of neutrophils and eosinophils scattered throughout tissue.

Supplementary Table S6. Effect of treatment on the histopathology of the tonsil palatine.

| Treatment Group | Placebo | Bacterial Cocktail |
|-------------------------------------|---------|--------------------|
| No lymphoid tissue collected | | |
| 24h after birth | 0/6 | 3/6 |
| 96h after birth | 0/6 | 0/6 |
| 14d after birth | 0/6 | 0/6 |
| No abnormalities | | |
| 24h after birth | 3/6 | 0/6 |
| 96h after birth | 0/6 | 0/6 |
| 14d after birth | 1/6 | 0/6 |
| *Non-significant findings | | |
| 24h after birth | 3/6 | 3/6 |
| 96h after birth | 6/6 | 6/6 |
| 14d after birth | 5/6 | 6/6 |

* Normal findings of neutrophils and eosinophils scattered throughout tissue and/or cellular debris and degenerate inflammatory cells in the crypts.

Supplementary Table S7. Effect of treatment on the histopathology of the left and right tonsil retropharyngeal.

| Treatment Group | Left | | Right | |
|-------------------------------------|---------|--------------------|---------|--------------------|
| | Placebo | Bacterial Cocktail | Placebo | Bacterial Cocktail |
| No lymphoid tissue collected | | | | |
| 24h after birth | 4/6 | 1/6 | 2/6 | 4/6 |
| 96h after birth | 3/6 | 3/6 | 1/6 | 4/6 |
| 14d after birth | 3/6 | 2/6 | 2/6 | 1/6 |
| No abnormalities | | | | |
| 24h after birth | 1/6 | 5/6 | 4/6 | 2/6 |
| 96h after birth | 1/6 | 1/6 | 1/6 | 1/6 |
| 14d after birth | 2/6 | 4/6 | 0/6 | 2/6 |
| *Non-significant findings | | | | |
| 24h after birth | 1/6 | 0/6 | 0/6 | 0/6 |
| 96h after birth | 2/6 | 2/6 | 4/6 | 1/6 |
| 14d after birth | 1/6 | 0/6 | 4/6 | 3/6 |

*Normal findings of neutrophils and eosinophils scattered throughout tissue and/or cellular debris and degenerate inflammatory cells in the crypts.